Drug Combination Details
| General Information of the Combination (ID: C06930) | |||||
|---|---|---|---|---|---|
| Name | Celastrol NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CERS1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CERS4 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CERS6 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | CT26 | CVCL_7254 | Mouse colon adenocarcinoma | Mus musculus | ||
| HCT 8 | CVCL_2478 | Colon adenocarcinoma | Homo sapiens | |||
| DLD-1 | CVCL_0248 | Colon adenocarcinoma | Homo sapiens | |||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| In-vivo Model | BALB/c mice were removed hair and injected CT26 cells (1.5*106) suspended in FBS: Matrigel (1:1, 200 uL/mouse) subcutaneously in the flank region of mice. | |||||
| Experimental
Result(s) |
Hydrogel-mediated delivery of celastrol and doxorubicin induces a synergistic effect on tumor regression via upregulation of ceramides. | |||||
